Arginase enzymes in the human prostate: A molecular biological and immunohistochemical approach.
arginase enzymes
immunohistochemistry
molecular biology
prostate smooth muscle
Journal
Andrologia
ISSN: 1439-0272
Titre abrégé: Andrologia
Pays: Germany
ID NLM: 0423506
Informations de publication
Date de publication:
Oct 2019
Oct 2019
Historique:
received:
22
03
2019
revised:
25
04
2019
accepted:
14
05
2019
entrez:
5
9
2019
pubmed:
5
9
2019
medline:
15
2
2020
Statut:
ppublish
Résumé
The nitric oxide (NO) pathway plays a role in maintaining the function of the prostate. An impairment in the activity of the NO system may have an impact in the manifestation of lower urinary tract symptomatology and benign prostatic hyperplasia. Arginase enzymes (Arg) counteract the generation of NO by depleting the intracellular pool of L-arginine, known to be the substrate of the NO synthases. This study investigated the expression of arginase type I and II in the human prostate. Nondiseased prostate tissue was obtained during pelvic surgeries (prostatectomy, cystoprostatectomy). Tissue sections were exposed to antibodies directed against Arg I and II, cGMP, the phosphodiesterase 5 and nNOS. The expression of mRNA transcripts encoding for Arg I and Arg II was investigated using molecular biology. Reverse transcriptase polymerase chain reaction (RT-PCR) revealed the presence of mRNA encoding for Arg I and II, immunofluorescence specific for Arg I was seen in the stromal smooth musculature, and labelling for PDE5 and cyclic GMP was also observed. Nerve fibres containing nNOS were identified running across the smooth musculature. Immunostainings for Arg II did not yield signals. These findings are in support of the notion that, in the prostate, Arg is involved in the modulation of the activity of the NO system.
Substances chimiques
RNA, Messenger
0
Nitric Oxide
31C4KY9ESH
Arginine
94ZLA3W45F
NOS1 protein, human
EC 1.14.13.39
Nitric Oxide Synthase Type I
EC 1.14.13.39
ARG1 protein, human
EC 3.5.3.1
ARG2 protein, human
EC 3.5.3.1
Arginase
EC 3.5.3.1
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e13349Informations de copyright
© 2019 Blackwell Verlag GmbH.
Références
Ash, D. E. (2004). Structure and function of arginases. The Journal of Nutrition, 134, 2760S-2764S. (Discussion 2765S-2767S).
Bloch, W., Klotz, T., Loch, C., Schmidt, G., Engelmann, U., & Addicks, K. (1997). Distribution of nitric oxide synthase implies a regulation of circulation, smooth muscle tone, and secretory function in the human prostate by nitric oxide. Prostate, 33, 1-8.
Burnett, A. L., Maguire, M. P., Chamness, S. L., Ricker, D. D., Takeda, M., Lepor, H., & Chang, T. S. (1995). Characterization and localization of nitric oxide synthase in the human prostate. Urology, 45, 435-439.
Durante, W., Johnson, F. K., & Johnson, R. A. (2007). Arginase: A critical regulator of nitric oxide synthesis and vascular function. Clinical and Experimental Pharmacology & Physiology, 34, 906-911.
Ghazalpour, A., Bennett, B., Petyuk, V. A., Orozco, L., Hagopian, R., Mungrue, I. N., … Lusis, A. J. (2011). Comparative analysis of proteome and transcriptome variation in mouse. PLoS Genetics, 7, e1001393.
Gradini, R., Realacci, M., Ginepri, A., Naso, G., Santangelo, C., Cela, O., … Russo, M. A. (1999). Nitric oxide synthases in normal and benign hyperplastic human prostate: Immunohistochemistry and molecular biology. The Journal of Pathology, 189, 224-229.
Harris, B., Pretlow, T. P., Bradley, Jr E. L., Whitehurst, G. B., & Pretlow, T. G. (1983). Arginase activity in prostatic tissue of patients with benign prostatic hyperplasia and prostatic carcinoma. Cancer Research, 43, 3008-3012.
Hedlund, P. (2005). Nitric oxide/cGMP-mediated effects in the outflow region of the lower urinary tract - Is there a basis for pharmacological targeting of cGMP? World Journal of Urology, 23(6), 362-367. https://doi.org/10.1007/s00345-005-0019-1
Hedlund, P., Ekstrom, P., Larsson, B., Alm, P., & Andersson, K. E. (1997). Heme oxygenase and NO-synthase in the human prostate-relation to adrenergic, cholinergic and peptide-containing nerves. Journal of the Autonomic Nervous System, 63, 115-126.
Kedia, G. T., Oelke, M., Sonnenberg, J. E., Sohn, M., Bannowsky, A., Kuczyk, M. A., & Ückert, S. (2014). Phosphodiesterase isoenzymes in the human urethra: A molecular biology and functional study. European Journal of Pharmacology, 741, 330-335.
Kedia, G. T., Sonnenberg, J. E., Kuczyk, M. A., & Ückert, S. (2012). Arginase enzymes in the human prostate: Expression of arginase isoenzymes and effects of arginase inhibitors on isolated human prostate tissue. BJU International, 110, e1196-e1201.
Kedia, G. T., Ückert, S., Jonas, U., Kuczyk, M. A., & Burchardt, M. (2008). The nitric oxide pathway in the human prostate: Clinical implications in men with lower urinary tract symptoms. World Journal of Urology, 26, 603-609.
Kedia, G. T., Ückert, S., Scheller, F., Chigogidze, T., Managadze, L., Jonas, U., & Truss, M. C. (2006). In vitro functional responses of isolated normal human prostatic tissue to compounds interacting with the cyclic guanosine monophosphate pathway.Urology, 67(6), 1292-1297. https://doi.org/10.1016/j.urology.2005.12.002
Küthe, A., Mägert, H., Ückert, S., Forssmann, W. G., Stief, C. G., & Jonas, U. (2000). Gene expression of the phosphodiesterases 2A and 5A in human corpus cavernosum penis. European Urology, 38, 108-114.
Lexander, H., Franzen, B., Hirschberg, D., Becker, S., Hellström, M., Bergman, T., … Egevad, L. (2005). Differential protein expression in anatomical zones of the prostate. Proteomics, 5, 2570-2576.
Ma, X. M., & Blenis, J. (2009). Molecular mechanisms of mTOR-mediated translational control. Nature Reviews. Molecular Cell Biology, 10, 307-518.
Morris, Jr S. M. (2002). Regulation of the enzymes of the urea cycle and arginine metabolism. Annual Review of Nutrition, 22, 87-105.
Morris, Jr S. M. (2009). Recent advances in arginine metabolism: Roles and regulation of the arginases. British Journal of Pharmacology, 157, 922-930.
Mumenthaler, S. M., Yu, H., Tze, S., Cederbaum, S. D., Pegg, A. E., Seligson, D. B., & Grody, W. W. (2008). Expression of arginase II in prostate cancer. International Journal of Oncology, 32, 357-365.
Munder, M. (2009). Arginase: An emerging key player in the mammalian immune system. British Journal of Pharmacology, 158, 638-651.
Reitz, A., Müntener, M., Haferkamp, A., Hohenfellner, M., & Schurch, B. (2005). Targeting bladder outlet obstruction from benign prostatic enlargement via the nitric oxide/cGMP pathway? BJU International, 96(3), 250-253. https://doi.org/10.1111/j.1464-410X.2005.05612.x
Reschner, A., Harlin, H., Laven, B., Eriksson, F., Pisa, P., & Egevad, L. (2009). Expression of immunomodulating genes in prostate cancer and benign prostatic tissue. Analytical and Quantitative Cytology and Histology, 31, 74-82.
Ribera, J., Ayala, V., & Esquerda, J. E. (2002). c-Jun-like immunoreactivity in apoptosis is the result of a cross-reaction with neo-antigenic sites exposed by caspase-3-mediated proteolysis. The Journal of Histochemistry and Cytochemistry, 50, 961-972.
Santhanam, L., Christianson, D. W., Nyhan, D., & Berkowitz, D. E. (2008). Arginase and vascular aging. Journal of Applied Physiology (Bethesda, Md.: 1985), 105, 1632-1642.
Sonenberg, N., & Hinnebusch, A. G. (2009). Regulation of translation initiation in eukaryotes: Mechanisms and biological targets. Cell, 136, 731-745.
Takeda, M., Tang, R., Shapiro, E., Burnett, A. L., & Lepor, H. (1995). Effects of nitric oxide on human and canine prostates. Urology, 1995(45), 440-446.
Ückert, S., Waldkirch, E. S., Merseburger, A. S., Kuczyk, M. A., Oelke, M., & Hedlund, P. (2013). Phosphodiesterase type 5 (PDE5) is co-localized with key proteins of the nitric oxide/cyclic GMP signalling in the human prostate. World Journal of Urology, 31, 609-614.
Venkatakrishnan, G., Shankar, V., & Reddy, S. R. (2003). Microheterogeneity of molecular forms of arginase in mammalian tissues. Indian Journal of Biochemistry & Biophysics, 40, 400-408.
Vogel, C., Abreu Rde, S., Ko, D., Le, S. Y., Shapiro, B. A., Burns, S. C., … Penalva, L. O. (2010). Sequence signatures and mRNA concentration can explain two-thirds of protein abundance variation in a human cell line. Molecular Systems Biology, 6, 400.
Waddington, S. N., & Cattell, V. (2000). Arginase in glomerulonephritis. Experimental Nephrology, 8, 128-134.
Wek, R. C., Jiang, H. Y., & Anthony, T. G. (2006). Coping with stress: eIF2 Kinases and translational control. Biochemical Society Transactions, 34, 7-11.
Zamecka, E., & Porembska, Z. (1988). Five forms of arginase in human tissues. Biochemical Medicine and Metabolic Biology, 39, 258-366.